Chemoinformaics analysis of isoalangimarine (benzopyrido-quinolizidines)
| Molecular Weight | 320.348 | nRot | 2 |
| Heavy Atom Molecular Weight | 304.22 | nRig | 23 |
| Exact Molecular Weight | 320.116 | nRing | 4 |
| Solubility: LogS | -4 | nHRing | 3 |
| Solubility: LogP | 3.171 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 40 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 2 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 17 |
| nHA | 5 | APOL | 47.0047 |
| nHD | 1 | BPOL | 21.5053 |
| QED | 0.788 |
| Synth | 2.9 |
| Natural Product Likeliness | 1.004 |
| NR-PPAR-gamma | 0.724 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.429 |
| Pgp-sub | 0.069 |
| HIA | 0.004 |
| CACO-2 | -4.933 |
| MDCK | 0.0000181 |
| BBB | 0.417 |
| PPB | 0.945264 |
| VDSS | 1.351 |
| FU | 0.0540551 |
| CYP1A2-inh | 0.979 |
| CYP1A2-sub | 0.896 |
| CYP2c19-inh | 0.757 |
| CYP2c19-sub | 0.244 |
| CYP2c9-inh | 0.75 |
| CYP2c9-sub | 0.89 |
| CYP2d6-inh | 0.711 |
| CYP2d6-sub | 0.919 |
| CYP3a4-inh | 0.896 |
| CYP3a4-sub | 0.496 |
| CL | 10.154 |
| T12 | 0.338 |
| hERG | 0.476 |
| Ames | 0.934 |
| ROA | 0.185 |
| SkinSen | 0.85 |
| Carcinogencity | 0.78 |
| EI | 0.254 |
| Respiratory | 0.908 |
| NR-Aromatase | 0.889 |
| Antiviral | Yes |
| Prediction | 0.85615 |